Rodney M. Camire

In This Section

Rodney M. Camire, PhD

Investigator

Dr. Camire's research focuses on understanding the components of the blood coagulation system, how they interface with activated cells, and how disturbances in their function lead to bleeding and thrombosis. He is also interested in developing novel therapeutic approaches (protein, gene-based, small molecule) to mitigate these events, which are major causes of morbidity and mortality worldwide.

AddtoAny

Bio

Dr. Camire is interested in understanding the components of the blood coagulation system, how they interface with activated cells, and how disturbances in their function lead to bleeding and thrombosis. His group is developing therapeutic approaches to mitigate these events, which are major causes of morbidity and mortality worldwide.

His current areas of investigation include understanding how clotting factor cofactors work, such as factor V and VIII, and defining their mechanism of activation. Dr. Camire's lab uncovered surprising observations that have fundamentally shifted current thinking about FV activation and its regulation by tissue factor pathway inhibitor.

Dr. Camire investigates structural correlates of protease function-basic and translational research to understand how processing of inactive serine protease zymogens, such as FX and FIX, to their active forms contribute to the expression of binding sites critical to their function. Knowledge from these biochemical studies has been applied to translational studies to develop novel protein therapeutics to treat bleeding in hemophilia, trauma, or other conditions.

Other current areas of investigation include imaging coagulation reactions. Dr. Camire uses fluorescence approaches developed for physical studies of coagulation enzyme function to develop enabling technologies that permit quantitative measurements of enzyme complex assembly and function in vivo. He also employs protein, gene therapy, and other strategies to alleviate hemophilia A or B. Using different bioengineering strategies, he aims to modify FVIII or FIX with unique properties that could be useful in a gene-based approach.

Dr. Camire has been funded from the NIH since 2003 and has published over 70 primary and review articles related to blood coagulation, and work from his laboratory has led to over 15 patents. Dr. Camire is a recent International Society on Thrombosis and Haemostasis Biennial Awards for Contributions to Hemostasis awardee, and he also sits on the Editorial Board of Blood.